Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of veteran RNA researcher Amanda Garner, Ph.D. to their Scientific Advisory Board (SAB).
“We are delighted to welcome Dr. Garner to our esteemed panel of Scientific Advisors, further strengthening our ability to execute on our mission to merge AI with structural biology to develop novel, more effective RNA medicines,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI. “Her wealth of research expertise and deep comprehension of RNA’s pivotal functions in human health maintenance and its implications in disease, will be profoundly impactful.”
Dr. Garner, an Associate Professor of Medicinal Chemistry and Director of the Interdepartmental Program in Medicinal Chemistry at the College of Pharmacy, University of Michigan, brings her extensive expertise in chemical biology, medicinal chemistry, and molecular and cellular biology to Atomic's Scientific Advisory Board. Her research focuses on innovative drug discovery efforts targeting RNAs and RNA-protein interactions for the development of next-generation medicines. As a co-inventor on four patents, author on over 65 publications, and speaker at more than 105 invited engagements, Dr. Garner is widely recognized and respected in the field of RNA biomedicine. Before joining the University of Michigan, she conducted research at The Scripps Research Institute for five years. As an accomplished speaker, educator, mentor, and editor, Dr. Garner has received numerous honors, awards, and fellowships, including the prestigious 2023 Ono Pharma Breakthrough Science Initiative Award and the 2022 David W. Robertson Award from the ACS Division of Medicinal Chemistry. Dr. Garner has also successfully secured substantial grant funding from several esteemed institutions to advance her research. She holds a Ph.D. in Chemistry from the University of Pittsburgh and graduated Magna cum Laude with a B.S. in Chemistry from Allegheny College.
“The potential of RNA in medicine is immense and can revolutionize patient care. Atomic’s collective expertise and pioneering platform approach to unravel how medicinal chemistry can influence RNA biology is destined to be paradigm-shifting for drug discovery and ultimately patients. I am thrilled to be part of the Atomic AI team," said Dr. Garner.
About Atomic AI
Atomic AI is an emerging biotechnology company exploiting the cutting-edge fusion of artificial intelligence and structural biology to unlock RNA drug discovery. Based on research prominently featured in Science, Atomic AI’s proprietary R&D platform leverages state-of-the-art deep learning foundation models integrated into a virtuous cycle with purpose-designed, in-house wet-lab assays, to discover and design proprietary 3D RNA structural datasets. Backed by an interdisciplinary team of machine learning researchers, medicinal chemists, engineers, and experimental biologists, as well as strategic scientific advisers and world-class investors, Atomic AI is leading the way in AI-augmented structural biology and transforming the design of RNA-targeted and RNA-based medicines to treat undruggable diseases. To learn more, visit atomic.ai and engage with us on LinkedIn and X.
Contact:
Susan Sharpe
Linnden Communications
susan@linndencom.com